PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
Open Access
- 1 January 2021
- journal article
- review article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 20
Abstract
Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy.Keywords
Funding Information
- Heilongjiang Touyan Innovation Team Program (2019HTY078)
This publication has 61 references indexed in Scilit:
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJournal of Leukocyte Biology, 2013
- The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and bloodNature Immunology, 2012
- Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanismsEuropean Journal of Immunology, 2011
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion VaccineJournal of Immunotherapy, 2011
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibodyBlood, 2010
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- The dual-function CD150 receptor subfamily: the viral attractionNature Immunology, 2003
- Activation-Induced Expression of Human Programmed Death-1 Gene in T-LymphocytesExperimental Cell Research, 1997
- Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)Genomics, 1994